<qa>  What is the name of the test that will allow secondary analyses of the impact of Apo EApolipoprotein E Apo E genotype will be determined at the screening visit to allow secondary analyses of the impact of Apo E genotype that may influence Alzheimers disease risk on outcome measures and the response to treatment. DNA specimens will also be stored for possible future genetic analyses, with trial sites allowing for non-participation in this procedure. Visits will occur at baseline and then at 6 monthly intervals, with each visit including interval medical history, current and interval medications, side effects checklist, adverse events, pill count, institutionalization status, cognitive, functional, and behavioral measures, and DSM-IV diagnostic assessment for Alzheimers disease. 